ArticleTranslational neuroscience2021
Nervonic acid amends motor disorder in a mouse model of Parkinson's disease.
Article in Translational neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 18 citations in OpenAlex.
- Erythrocyte membrane nervonic acid in drug-naive first-episode psychosis and chronic medicated schizophrenia: Implication for impaired myelination and prognosis.World journal of psychiatry · 2025Article
- Erucic acid utilization byFrontiers in microbiology · 2024Article
- Nervonic acid reduces the cognitive and neurological disturbances induced by combined doses of D-galactose/AlClFood science & nutrition · 2023Article
- DHA-Enriched Fish Oil Ameliorates Deficits in Cognition Associated with Menopause and theNutrients · 2022Article
- Oriented Deep Eutectic Solvents as Efficient Approach for Selective Extraction of Bioactive Saponins from Husks ofAntioxidants (Basel, Switzerland) · 2022Article
- Nervonic Acid Attenuates Accumulation of Very Long-Chain Fatty Acids and is a Potential Therapy for Adrenoleukodystrophy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Article
- Embelin and levodopa combination therapy for improved Parkinson's disease treatment.Translational neuroscience · 2022Article
Corrections and comments
- Retraction · 2022-04-20Duplication of/in Article · Ethical Violations by Author ·
- Retracted
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesParkinson's disease (PD) is a kind of common neurodegenerative disease in the world. Previous studies have proved that nervonic acid (NA), extracted from
methods1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was used for producing parkinsonism motor disorder on male C57BL/6 mice. Toxicity experiments and behavioral assay were performed to evaluate the effect of NA. Besides, the expression levels of tyrosine hydroxylase and α-synuclein, as well as striatal dopamine (DA), serotonin, and their metabolites were explored through immunoblotting and chromatography after NA treatment
resultsWe found that NA could alleviate the MPTP-induced behavioral deficits dose-dependently. Moreover, NA has no toxic effects on the mouse liver and kidney. Of note, we found that NA significantly reduced the impact of MPTP impairment and striatal DA, serotonin, and metabolites were remained unaffected. In addition, tyrosine hydroxylase was upregulated while α-synuclein being downregulated and the oxidative stress was partially repressed evidenced by the upregulation of superoxide dismutase and glutathione activity after NA treatment.
conclusionOur findings unveil NA's potential for protecting motor system against motor disorder in the PD mouse model without any side effects, indicating NA as an alternative strategy for PD symptom remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.